Purchase this article with an account.
Joshua C. Priluck, K V. Chalam, Sandeep Grover; Macular Volume Change By Spectral-domain Optical Coherence Tomography After Treatment With Bevacizumab in Exudative Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):801.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the change in macular volume as well as macular thickness by Spectral-domain optical coherence tomography (SD-OCT / Spectralis) in patients with exudative age-related macular degeneration (AMD) in response to treatment with intravitreal bevacizumab.
This was a retrospective study where the patients with exudative AMD who had been treated with intravitreal bevacizumab were identified. SD-OCT recordings done at initial treatment and after at least 3 months of follow-up were utilized for the measurements. Patients with diabetes or who underwent eye surgery during this period were excluded. Initial and final total macular volumes and central macular thickness (CMT) were recorded. Paired t-test was performed to analyze change in total macular volume and CMT for statistical significance.
37 eyes of 35 patients were included in the study. The average initial macular volume was 2.58 mm3 (+/- 0.52) and final was 2.35 mm3 (+/- 0.39) - the change in volume was a decrease by 0.22 mm3 (+/- 0.46). Using a paired t-test the t-value was 0.0055, which is significant. The mean initial CMT was 377 micrometers (+/- 119) and final 327 micrometers (+/- 86.4) - the change in CMT was a decrease of 49.7 micrometers (+/- 108). Using a paired t-test the t-value was 0.0082, which is significant. The mean follow-up period ranged from 91 to 1372 days with mean 493 days (+/-341) and median of 416 days.
Patients with exudative AMD treated with bevacizumab not only show significantly reduced macular thickness but also 'total macular volume' after treatment with intravitreal bevacizumab. Volumetric measurement of macular thickness may be a useful additional tool in monitoring the treatment or course of the disease in exudative AMD.
This PDF is available to Subscribers Only